155 related articles for article (PubMed ID: 28607607)
1. MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion.
Ju L; Han M; Li X; Zhao C
J Cancer; 2017; 8(7):1311-1318. PubMed ID: 28607607
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide DNA Methylation Analysis Reveals
Niu X; Liu F; Zhou Y; Zhou Z; Zhou D; Wang T; Li Z; Ye X; Yu Y; Weng X; Zhang H; Ye J; Liao M; Liu Y; Chen Z; Lu S
Clin Cancer Res; 2017 Sep; 23(17):5003-5014. PubMed ID: 28490462
[No Abstract] [Full Text] [Related]
3. Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway.
Han Z; Zhou X; Li S; Qin Y; Chen Y; Liu H
Oncol Rep; 2017 Nov; 38(5):3064-3070. PubMed ID: 28901474
[TBL] [Abstract][Full Text] [Related]
4. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
5. Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation.
Wang S; Su X; Bai H; Zhao J; Duan J; An T; Zhuo M; Wang Z; Wu M; Li Z; Zhu J; Wang J
J Hematol Oncol; 2015 Nov; 8():127. PubMed ID: 26563758
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
7. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
8. Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI.
Ma Y; Pan X; Xu P; Mi Y; Wang W; Wu X; He Q; Liu X; Tang W; An HX
Oncotarget; 2017 Oct; 8(51):88529-88536. PubMed ID: 29179454
[TBL] [Abstract][Full Text] [Related]
9. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
Zhao J; Guerrero A; Kelnar K; Peltier HJ; Bader AG
Lung Cancer; 2017 Jun; 108():96-102. PubMed ID: 28625657
[TBL] [Abstract][Full Text] [Related]
10. Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.
Qu L; Li L; Zheng X; Fu H; Tang C; Qin H; Li X; Wang H; Li J; Wang W; Yang S; Wang L; Zhao G; Lv P; Lei Y; Zhang M; Gao H; Song S; Liu X
Oncotarget; 2017 Jul; 8(28):45807-45824. PubMed ID: 28496005
[TBL] [Abstract][Full Text] [Related]
11. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of miR-185-3p Confers Erlotinib Resistance Through Upregulation of PFKL/MET in Lung Cancers.
Li K; Zhu X; Yuan C
Front Cell Dev Biol; 2021; 9():677860. PubMed ID: 34368128
[TBL] [Abstract][Full Text] [Related]
13. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
[TBL] [Abstract][Full Text] [Related]
14. Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers.
Zhao Q; Cao J; Wu YC; Liu X; Han J; Huang XC; Jiang LH; Hou XX; Mao WM; Ling ZQ
Am J Cancer Res; 2015; 5(5):1692-705. PubMed ID: 26175938
[TBL] [Abstract][Full Text] [Related]
15. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway.
Ma W; Kang Y; Ning L; Tan J; Wang H; Ying Y
Exp Ther Med; 2017 Oct; 14(4):2853-2862. PubMed ID: 28912847
[TBL] [Abstract][Full Text] [Related]
16. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
[No Abstract] [Full Text] [Related]
17. MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells.
Jiang L; Chang J; Zhang Q; Sun L; Qiu X
Cancer Invest; 2013 Oct; 31(8):538-44. PubMed ID: 24044511
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells.
Jiang L; Huang Q; Chang J; Wang E; Qiu X
Exp Lung Res; 2011 Sep; 37(7):387-98. PubMed ID: 21777146
[TBL] [Abstract][Full Text] [Related]
19. Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.
Bisagni A; Pagano M; Maramotti S; Zanelli F; Bonacini M; Tagliavini E; Braglia L; Paci M; Mozzarelli A; Croci S
PLoS One; 2018; 13(4):e0196350. PubMed ID: 29689091
[TBL] [Abstract][Full Text] [Related]
20. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.
Cho WC; Chow AS; Au JS
Eur J Cancer; 2009 Aug; 45(12):2197-206. PubMed ID: 19493678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
